Revolution Medicines (RVMD) Change in Receivables (2020 - 2024)
Revolution Medicines' (RVMD) quarterly Change in Receivables came in at -$1.3 million in Q1 2024, down 84.96% year-on-year from -$8.3 million in Q2 2023, and down 232.7% quarter-over-quarter from $945000.0 in Q4 2023.
Revolution Medicines (RVMD) Change in Receivables (2020 - 2024) Analysis & Trends
Revolution Medicines' Change in Receivables history runs 5 years deep, the most recent figure standing at -$1.3 million for Q1 2024.
- On a quarterly basis, Change in Receivables fell 84.96% year-over-year to -$1.3 million in Q1 2024; TTM through Dec 2024 was -$1.3 million, a 63.32% increase from a year earlier, with the FY2024 full-year figure at -$1.3 million, up 63.32% from the prior year.
- Change in Receivables retreated to -$1.3 million in Q1 2024 per RVMD's latest filing, from $945000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $2.0 million in Q3 2020 and bottomed at -$2.9 million in Q4 2020.
- The 5-year median for Change in Receivables is -$678000.0 (2023), against an average of -$513941.2.
- Across the five-year window, Change in Receivables surged 508.01% in 2021 and slumped 716.18% in 2023, its largest moves.
- Year by year, Change in Receivables stood at -$2.9 million in 2020, then surged by 48.97% to -$1.5 million in 2021, then surged by 82.0% to -$267000.0 in 2022, then jumped by 453.93% to $945000.0 in 2023, then slumped by 232.7% to -$1.3 million in 2024.
- Per Business Quant, the three latest RVMD Change in Receivables figures stand at -$1.3 million (Q1 2024), $945000.0 (Q4 2023), and -$2.2 million (Q3 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 110.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -1.25 Mn |
| Mar 31, 2024 | -1.25 Mn |
| Dec 31, 2023 | 945,000.00 |
| Dec 31, 2023 | 945,000.00 |
| Sep 30, 2023 | -2.20 Mn |
| Sep 30, 2023 | -2.20 Mn |
| Jun 30, 2023 | -1.49 Mn |
| Jun 30, 2023 | -1.49 Mn |
| Mar 31, 2023 | -678,000.00 |
| Mar 31, 2023 | -678,000.00 |
| Dec 31, 2022 | -267,000.00 |
| Dec 31, 2022 | -267,000.00 |
| Sep 30, 2022 | -684,000.00 |
| Sep 30, 2022 | -684,000.00 |
| Jun 30, 2022 | 241,000.00 |
| Jun 30, 2022 | 241,000.00 |
| Mar 31, 2022 | -546,000.00 |
| Mar 31, 2022 | -546,000.00 |
| Dec 31, 2021 | -1.48 Mn |
| Dec 31, 2021 | -1.48 Mn |